| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Allègre to upset science and education in France
|
|
|
|
9 |
10 |
p. 1041
|
article
|
| 2 |
An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
|
Degardin, M.
|
|
|
9 |
10 |
p. 1103-1107
|
article
|
| 3 |
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer
|
Vokes, E.E.
|
|
|
9 |
10 |
p. 1085-1090
|
article
|
| 4 |
A phase II study of 9-aminocamptothecin in advanced non-small-cell lungcancer
|
E. E. Vokes
|
|
1998
|
9 |
10 |
p. 1085-1090
6 p.
|
article
|
| 5 |
A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas
|
Garcia, A.A.
|
|
|
9 |
10 |
p. 1131-1133
|
article
|
| 6 |
A phase II study of Doxil (liposomal doxorubicin): Lack of activity inpoor prognosis soft tissue sarcomas
|
A. A. Garcia
|
|
1998
|
9 |
10 |
p. 1131-1133
3 p.
|
article
|
| 7 |
A replica of FECS in the US
|
|
|
|
9 |
10 |
p. 1040-1041
|
article
|
| 8 |
Assessment of response in primary chemotherapy for breast cancer
|
Colleoni, M.
|
|
|
9 |
10 |
p. 1140-1141
|
article
|
| 9 |
Assessment of response in primary chemotherapy for breast cancer
|
M. Colleoni
|
|
1998
|
9 |
10 |
p. 1140-1141
2 p.
|
article
|
| 10 |
Awards, appointments
|
|
|
|
9 |
10 |
p. 1041-1042
|
article
|
| 11 |
Book review
|
Sternberg, C.
|
|
|
9 |
10 |
p. 1044
|
article
|
| 12 |
Book review
|
Geffen, D.B.
|
|
|
9 |
10 |
p. 1142
|
article
|
| 13 |
Book review
|
Obrist, R.
|
|
|
9 |
10 |
p. 1043
|
article
|
| 14 |
Brundtland sweeps through WHO
|
|
|
|
9 |
10 |
p. 1039-1040
|
article
|
| 15 |
Contents of the next issue
|
|
|
|
9 |
10 |
p. v
|
article
|
| 16 |
Copyright
|
|
|
|
9 |
10 |
p. iii
|
article
|
| 17 |
Corrigendum
|
|
|
|
9 |
10 |
p. 1143
|
article
|
| 18 |
Dose-intensified weekly paclitaxel induces multiple nail disorders
|
Lüftner, D.
|
|
|
9 |
10 |
p. 1139-1140
|
article
|
| 19 |
Dose-intensified weekly paclitaxel induces multiple nail disorders
|
D. Lüftner
|
|
1998
|
9 |
10 |
p. 1139-1140
2 p.
|
article
|
| 20 |
Editorial board
|
|
|
|
9 |
10 |
p. iv
|
article
|
| 21 |
Formula 1, an ideal vector for smoking
|
|
|
|
9 |
10 |
p. 1040
|
article
|
| 22 |
Frequency and significance of anemia in non-Hodgkin’s lymphoma patients
|
Moullet, I.
|
|
|
9 |
10 |
p. 1109-1115
|
article
|
| 23 |
Frequency and significance of anemia in non-Hodgkins lymphomapatients
|
I. Moullet
|
|
1998
|
9 |
10 |
p. 1109-1115
7 p.
|
article
|
| 24 |
In this Issue
|
|
|
|
9 |
10 |
p. v
|
article
|
| 25 |
K. Offit (ed), Clinical cancer genetics: Risk counselling andmanagement
|
D. B. Geffen
|
|
1998
|
9 |
10 |
p. 1142-1142
1 p.
|
article
|
| 26 |
K. Redmond, M. S Aapro (eds), Cancer in the elderly. A nursing andmedical perspective.
|
R. Obrist
|
|
1998
|
9 |
10 |
p. 1043-1043
1 p.
|
article
|
| 27 |
Major cuts for Dutch research
|
|
|
|
9 |
10 |
p. 1039
|
article
|
| 28 |
More money for cancer treatment requested in the UK
|
|
|
|
9 |
10 |
p. 1039
|
article
|
| 29 |
More money for cancer treatment requested in the UK; Major cuts for Dutchresearch; Brundtland sweeps through WHO; Formula 1, an ideal vector forsmoking; A replica of FECS in the US; New bill will render terminal care moredifficult in the US?; Allègre to upset science and education in France;Awards, appointments; Perhaps not everyone knows that...
|
|
|
1998
|
9 |
10 |
p. 1039-1043
5 p.
|
article
|
| 30 |
New bill will render terminal care more difficult in the US?
|
|
|
|
9 |
10 |
p. 1041
|
article
|
| 31 |
Oxaliplatin: A review of preclinical and clinical studies
|
Raymond, E.
|
|
|
9 |
10 |
p. 1053-1071
|
article
|
| 32 |
Oxaliplatin: A review of preclinical and clinical studies
|
E. Raymond
|
|
1998
|
9 |
10 |
p. 1053-1071
19 p.
|
article
|
| 33 |
P. C. Hoffman, D. J. Haraf, M. K. Ferguson, L. C. Drinkard & E. E.Vokes. Induction chemotherapy, surgery, and concomitant chemoradiotherapy forcarcinoma of the esophagus: A long-term analysis. Ann Oncol 9 (6):64751.
|
|
|
1998
|
9 |
10 |
p. 1143-1143
1 p.
|
article
|
| 34 |
Perhaps not everyone knows that…
|
|
|
|
9 |
10 |
p. 1042-1043
|
article
|
| 35 |
Phase I and II trials of novel anti-cancer agents: Endpoints, efficacyand existentialism
|
E. A. Eisenhauer
|
|
1998
|
9 |
10 |
p. 1047-1052
6 p.
|
article
|
| 36 |
Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism
|
Eisenhauer, E.A.
|
|
|
9 |
10 |
p. 1047-1052
|
article
|
| 37 |
Preparing guidelines and documented clinical policies
|
Haward, R.A.
|
|
|
9 |
10 |
p. 1073-1078
|
article
|
| 38 |
Preparing guidelines and documented clinical policies
|
R. A. Haward
|
|
1998
|
9 |
10 |
p. 1073-1078
6 p.
|
article
|
| 39 |
Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer
|
Sekine, I.
|
|
|
9 |
10 |
p. 1079-1084
|
article
|
| 40 |
Response rate as an endpoint for evaluating new cytotoxic agents in phaseII trials of non-small-cell lung cancer
|
I. Sekine
|
|
1998
|
9 |
10 |
p. 1079-1084
6 p.
|
article
|
| 41 |
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study
|
Androulakis, N.
|
|
|
9 |
10 |
p. 1127-1130
|
article
|
| 42 |
Salvage treatment with paclitaxel and gemcitabine for patients withnon-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy:A multicenter phase II study
|
N. Androulakis
|
|
1998
|
9 |
10 |
p. 1127-1130
4 p.
|
article
|
| 43 |
Table of Contents
|
|
|
|
9 |
10 |
p. ii-iii
|
article
|
| 44 |
Tamoxifen in liver disease: Potential exacerbation of hepatic dysfunction
|
Floren, L.C.
|
|
|
9 |
10 |
p. 1123-1126
|
article
|
| 45 |
Tamoxifen in liver disease: Potential exacerbation of hepaticdysfunction
|
L. C. Floren
|
|
1998
|
9 |
10 |
p. 1123-1126
4 p.
|
article
|
| 46 |
The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma
|
Zanetta, G.
|
|
|
9 |
10 |
p. 1097-1101
|
article
|
| 47 |
The accuracy of staging: An important prognostic determinator in stageI ovarian carcinoma
|
G. Zanetta
|
|
1998
|
9 |
10 |
p. 1097-1101
5 p.
|
article
|
| 48 |
The cognitive-spiritual dimension – an important addition to the assessment of quality of life: Validation of a questionnaire (SELT-M) in patients with advanced cancer
|
van Wegberg, B.
|
|
|
9 |
10 |
p. 1091-1096
|
article
|
| 49 |
The cognitive-spiritual dimension an important addition to theassessment of quality of life: Validation of a questionnaire (SELT-M) inpatients with advanced cancer
|
B. van Wegberg
|
|
1998
|
9 |
10 |
p. 1091-1096
6 p.
|
article
|
| 50 |
The fine points of end points: Phase II trials in ling cancer
|
K.A. Gelmon
|
|
1998
|
9 |
10 |
p. 1045-1046
2 p.
|
article
|
| 51 |
The fine points of end points: Phase II trials in lung cancer
|
Gelmon, K.A.
|
|
|
9 |
10 |
p. 1045-1046
|
article
|
| 52 |
Treatment of AIDS-related non-Hodgkin’s lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: Clinical outcome and effect on HIV-1 viral load
|
Kersten, M.J.
|
|
|
9 |
10 |
p. 1135-1138
|
article
|
| 53 |
Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease
|
Bangerter, M.
|
|
|
9 |
10 |
p. 1117-1122
|
article
|
| 54 |
Z. Petrovich, L. Baert, L. W. Brady (eds), Carcinoma of the bladder.Innovations in management.
|
C. Sternberg
|
|
1998
|
9 |
10 |
p. 1044-1044
1 p.
|
article
|
Journal description